Impaired periamygdaloid-cortex prodynorphin is characteristic of opiate addiction and depression

Journal of Clinical Investigation

Volumn 123, Issue 12, 2013, Pages 5334-5341

  Anderson, Sarah Ann R ^a   Michaelides, Michael ^a   Zarnegar, Parisa ^b   Ren, Yanhua ^a   Fagergren, Pernilla ^b   Thanos, Panayotis K ^c   Wang, Gene Jack ^d   Bannon, Michael ^e   Neumaier, John F ^f   Keller, Eva ^g   Volkow, Nora D ^c   Hurd, Yasmin L ^a,h  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^d STONY BROOK UNIVERSITY   (United States)

^e WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g SEMMELWEIS UNIVERSITY   (Hungary)

^h VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAMORPHINE; MESSENGER RNA; OPIATE; PRODYNORPHIN;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR CHANGE; BRAIN DYSFUNCTION; BRAIN LEVEL; BRAIN MAPPING; CONTROLLED STUDY; CORTICAL AMYGDALA; DRUG SELF ADMINISTRATION; FUNCTIONAL NEUROIMAGING; HEROIN DEPENDENCE; HUMAN; IN VIVO STUDY; MAJOR DEPRESSION; MALE; NEUROMODULATION; NONHUMAN; OPIATE ADDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ADULT; AMYGDALA; ANIMALS; CLOZAPINE; CORTICOSTERONE; DEPRESSIVE DISORDER, MAJOR; DESIGNER DRUGS; ENKEPHALINS; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; HEROIN DEPENDENCE; HUMANS; HUNGARY; LIMBIC SYSTEM; MALE; MIDDLE AGED; NEUROIMAGING; NEURONS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN PRECURSORS; RADIOPHARMACEUTICALS; RATS; RATS, LONG-EVANS; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; UNITED STATES;

EID: 84890106202     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI70395     Document Type: Article

References (56)

1. Koob GF, Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology. 2001;24(2):97-129.
2. Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol. 1988;54(6):1063-1070.
3. Martins SS, Fenton MC, Keyes KM, Blanco C, Zhu H, Storr CL. Mood and anxiety disorders and their association with non-medical prescription opioid use and prescription opioid-use disorder: longitudinal evidence from the National Epidemiologic Study on Alcohol and Related Conditions. Psychol Med. 2012;42(6):1261-1272.
4. Swendsen J, et al. Mental disorders as risk factors for substance use, abuse and dependence: results from the 10-year follow-up of the National Comorbidity Survey. Addiction. 2010;105(6):1117-1128.
5. Conway KP, Compton W, Stinson FS, Grant BF. Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2006;67(2):247-257.
6. Grant S, et al. Activation of memory circuits during cue-elicited cocaine craving. Proc Natl Acad Sci U S A. 1996;93(21):12040-12045.
7. Siegle GJ, Thompson W, Carter CS, Steinhauer SR, Thase ME. Increased amygdala and decreased dorsolateral prefrontal BOLD responses in unipolar depression: related and independent features. Biol Psychiatry. 2007;61(2):198-209.
8. Volkow ND, et al. Association of methylphe- nidate-induced craving with changes in right striato-orbitofrontal metabolism in cocaine abusers: implications in addiction. Am J Psychiatry. 1999;156(1):19-26.
9. Drevets WC, Bogers W, Raichle ME. Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism. Eur Neuropsychopharmacol. 2002;12(6):527-544.
10. Drevets WC, Price JL, Bardgett ME, Reich T, Todd RD, Raichle ME. Glucose metabolism in the amygdale in depression: relationship to diagnostic subtype plasma cortisol levels. Pharmacol Biochem Behav. 2002;71(3):431-447.
11. Brothers L, Ring B, Kling A. Response of neurons in the macaque amygdala to complex social stimuli. Behav Brain Res. 1990;41(3):199-213.
12. Greer CA, Stewart WB, Teicher MH, Shepherd GM. Functional development of the olfactory bulb a unique glomerular complex in the neonatal rat. J Neurosci. 1982;2(12):1744-1759.
13. Koob GF. Brain stress systems in the amygdala and addiction. Brain Res. 2009;1293:61-75.
14. Merchenthaler I, Maderdrut JL, Cianchetta P, Shughrue P, Bronstein D. In situ hybridization histochemical localization of prodynorphin messenger RNA in the central nervous system of the rat. J Comp Neurol. 1997;384(2):211-232.
15. Butelman ER, Yuferov V, Kreek MJ. κ-Opioid receptor/ dynorphin system: genetic and pharmacotherapeutic implications for addiction. Trends Neurosci. 2012;35(10):587-596.
16. Knoll AT, Carlezon WA Jr. Dynorphin, stress, and depression. Brain Res. 2010;1314:56-73.
17. Bruchas MR, Land BB, Chavkin C. The dynorphin/ kappa opioid system as a modulator of stressinduced and pro-addictive behaviors. Brain Res. 2010;1314:44-55.
18. Solecki W, Ziolkowska B, Krowka T, Gieryk A, Filip M, Przewlocki R. Alterations of prodynorphin gene expression in the rat mesocorticolimbic system during heroin self-administration. Brain Res. 2009;1255:113-121.
19. Turchan J, Maj M, Przewłocka B, Przewłocki R. Effect of cocaine amphetamine on biosynthesis of proenkephalin prodynorphin in some regions of the rat limbic system. Pol J Pharmacol. 2002;54(4):367-372.
20. D'Addario C, Di Benedetto M, Izenwasser S, Candeletti S, Romualdi P. Role of serotonin in the regulation of the dynorphinergic system by a kappa- opioid agonist cocaine treatment in rat CNS. Neuroscience. 2007;144(1):157-164.
21. Okvist A, et al. Dysregulated postsynaptic density endocytic zone in the amygdala of human heroin cocaine abusers. Biol Psychiatry. 2011;69(3):245-252.
22. Hurd YL. Differential messenger RNA expression of prodynorphin and proenkephalin in the human brain. Neuroscience. 1996;72(3):767-783.
23. Ellgren M, Spano SM, Hurd YL. Adolescent cannabis exposure alters opiate intake and opioid limbic neuronal populations in adult rats. Neuropsychopharmacology. 2007;32(3):607-615.
24. Contarino A, Papaleo F. The corticotropin-releasing factor receptor-1 pathway mediates the negative affective states of opiate withdrawal. Proc Natl Acad Sci U S A. 2005;102(51):18649-18654.
25. McNally GP, Akil H. Role of corticotropin-releasing hormone in the amygdala and ed nucleus of the stria terminalis in the behavioral, pain modulatory, and endocrine consequences of opiate withdrawal. Neuroscience. 2002;112(3):605-617.
26. Armbruster BN, Li X, Pausch MH, Herlitze S, Roth BL. Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. Proc Natl Acad Sci U S A. 2007;104(12):5163-5168.
27. Michaelides M, et al. Whole-brain circuit dissection in free-moving animals reveals cell-specific mesocorticolimbic networks. J Clin Invest. 2013;123(12):5342-5350.
28. Ferguson SM, et al. Transient neuronal inhibition reveals opposing roles of indirect direct pathways in sensitization. Nat Neurosci. 2011;14(1):22-24.
29. Alheid GF, Heimer L. New perspectives in basal forebrain organization of special relevance for neuropsychiatric disorders: the striatopallidal, amygdaloid, and corticopetal components of substantia innominata. Neuroscience. 1988;27(1):1-39.
30. Siebner H, et al. Activation of frontal premotor areas during suprathreshold transcranial magnetic stimulation of the left primary sensorimotor cortex: a glucose metabolic PET study. Hum Brain Mapp. 2001;12(3):157-167.
31. Thorens B. Brain glucose sensing and neural regulation of insulin and glucagon secretion. Diabetes Obes Metab. 2011;13(suppl 1):82-88.
32. Volonté MA, et al. Changes in brain glucose metabolism in subthalamic nucleus deep brain stimulation for advanced Parkinson's disease. Parkinsonism Relat Disord. 2012;18(6):770-774.
33. Casteels C, Lauwers E, Bormans G, Baekelandt V, Van Laere K. Metabolic-dopaminergic mapping of the 6-hydroxydopamine rat model for Parkinson's disease. Eur J Nucl Med Mol Imaging. 2008; 35(1):124-134.
34. Slattery DA, Cryan JF. Using the rat forced swim test to assess antidepressant-like activity in rodents. Nat Protoc. 2012;7(6):1009-1014.
35. Koob GF. A role for brain stress systems in addiction. Neuron. 2008;59(1):11-34.
36. Karpyak VM, et al. Association of the PDYN gene with alcohol dependence and the propensity to drink in negative emotional states. Int J Neuropsychopharmacol. 2013;16(5):975-985.
37. Yuferov V, et al. A functional haplotype implicated in vulnerability to develop cocaine dependence is associated with reduced PDYN expression in human brain. Neuropsychopharmacology. 2009;34(5):1185-1197.
38. Hurd YL. Subjects with major depression or bipolar disorder show reduction of prodynorphin mRNA expression in discrete nuclei of the amygdaloid complex. Mol Psychiatry. 2002;7(1):75-81.
39. Hurd YL, Herman MM, Hyde TM, Bigelow LB, Weinberger DR, Kleinman JE. Prodynorphin mRNA expression is increased in the patch vs matrix compartment of the caudate nucleus in suicide subjects. Mol Psychiatry. 1997;2(6):495-500.
40. Drakenberg K, et al. Mu opioid receptor A118G polymorphism in association with striatal opioid neuropeptide gene expression in heroin abusers. Proc Natl Acad Sci U S A. 2006;103(20):7883-7888.
41. Bruchas MR, et al. Stress-induced p38 mitogenactivated protein kinase activation mediates kappa-opioid-dependent dysphoria. J Neurosci. 2007;27(43):11614-11623.
42. Land BB, Bruchas MR, Lemos JC, Xu M, Melief EJ, Chavkin C. The dysphoric component of stress is encoded by activation of the dynorphin kappaopioid system. J Neurosci. 2008;28(2):407-414.
43. Bilkei-Gorzo A, Racz I, Michel K, Zimmer A, Klingmüller D, Zimmer A. Behavioral phenotype of pre-proenkephalin-deficient mice on diverse congenic backgrounds. Psychopharmacology (Berl). 2004;176(3-4):343-352.
44. Femenía T, Pérez-Rial S, Urigüen L, Manzanares J. Prodynorphin gene deletion increased anxiety-like behaviours, impaired the anxiolytic effect of bromazepam and altered GABAA receptor subunits gene expression in the amygdala. J Psychopharmacol. 2011;25(1):87-96.
45. Weiss F, et al. Compulsive drug-seeking behavior and relapse. Neuroadaptation, stress, and conditioning factors. Ann N Y Acad Sci. 2001;937:1-26.
46. Koob GF, Le Moal M. Plasticity of reward neurocircuitry and the 'dark side' of drug addiction. Nat Neurosci. 2005;8(11):1442-1444.
47. Koob GF. Roles for the extended amygdala in the reinforcing and aversive effects of drugs of abuse. Neuropsychopharmacology. 2004;29(S1):S67.
48. Oler JA, et al. Evidence for coordinated functional activity within the extended amygdale of non-human human primates. Neuroimage. 2012;61(4):1059-1066.
49. van Marle HJ, Tendolkar I, Urner M, Verkes RJ, Fernández G, van Wingen G. Subchronic duloxetine administration alters the extended amygdale circuitry in healthy individuals. Neuroimage. 2011;55(2):825-831.
50. Knoll AT, et al. Kappa opioid receptor signaling in the basolateral amygdala regulates conditioned fear and anxiety in rats. Biol Psychiatry. 2011;70(5):425-433.
51. McDonald AJ. Cortical pathways to the mammalian amygdala. Prog Neurobiol. 1998;55(3):257-332.
52. Pitkänen A, Savander V, LeDoux JE. Organization of intra-amygdaloid circuitries in the rat: an emerging framework for understanding functions of the amygdala. Trends Neurosci. 1997;20(11):517-523.
53. Jacobs MM, et al. Dopamine receptor D1 postsynaptic density gene variants associate with opiate abuse striatal expression levels [published online ahead of print October 9, 2012]. Mol Psychiatry. doi:10.1038/mp.2012.140.
54. Sillivan SE, et al. ELK1 transcription factor linked to dysregulated striatal mu opioid receptor signaling network OPRM1 polymorphism in human heroin abusers. Biol Psychiatry. 2013;74(7):511-519.
55. Tomasiewicz HC, Jacobs MM, Wilkinson MB, Wilson SP, Nestler EJ, Hurd YL. Proenkephalin mediates the enduring effects of adolescent cannabis exposure associated with adult opiate vulnerability. Biol Psychiatry. 2012;72(10):803-810.
56. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-tiome quantitative PCR and the 2(-delta delta C(T)) method. Methods. 2001;25(4):402-408.